What are the recommended dosing regimens and pharmacologic differences between mometasone furoate nasal spray and fluticasone propionate nasal spray?

Mometasone vs Fluticasone Nasal Spray: Dosing and Differences

Both mometasone furoate and fluticasone propionate nasal sprays are highly effective intranasal corticosteroids with similar clinical efficacy for allergic rhinitis, but they differ in their standard dosing regimens and have subtle pharmacologic distinctions that rarely impact clinical outcomes.

Standard Dosing Regimens

Fluticasone Propionate 1

• Adults and children ≥12 years: 2 sprays per nostril once daily (200 mcg total daily dose)
  • Can reduce to 1 spray per nostril once daily for maintenance after symptoms controlled
• Children 4-11 years: 1 spray per nostril once daily (100 mcg total daily dose)
• Duration limits:
  • Adults/adolescents: Up to 6 months of continuous use before physician consultation
  • Children 4-11: Up to 2 months per year before physician consultation (due to potential growth velocity concerns)

Mometasone Furoate 2

• Adults and children ≥12 years: 2 sprays per nostril once daily (200 mcg total daily dose)
• Children 2-11 years: 1 spray per nostril once daily (100 mcg total daily dose)
• Provides 24-hour relief of nasal congestion, runny nose, sneezing, and itchy nose

Key practical difference: Mometasone is FDA-approved for children as young as 2 years, while fluticasone propionate starts at age 4.

Pharmacologic Differences

Systemic Bioavailability

The most clinically relevant pharmacologic distinction relates to systemic exposure, though both agents have very low bioavailability:

• Intranasal bioavailability: Both drugs demonstrate similarly low systemic absorption when used intranasally at therapeutic doses 3, 4

  • Mometasone furoate: ~0.1% systemic bioavailability
  • Fluticasone propionate: Similar low bioavailability

• At therapeutic doses (200 mcg/day): Neither agent produces clinically significant HPA axis suppression 3

However, at supratherapeutic doses (800 mcg/day), important differences emerge 5:

• Mometasone furoate produced 35% cortisol suppression (2-fold greater than fluticasone propionate at 18%)
• This difference is attributed to mometasone's active metabolites (6β-hydroxy mometasone), higher glucocorticoid receptor binding affinity, and lower plasma clearance

Receptor Binding and Anti-inflammatory Activity

• Glucocorticoid receptor binding affinity: Mometasone furoate has the highest binding affinity among intranasal steroids, followed by fluticasone propionate 6
• Anti-inflammatory potency: Both demonstrate strong IL-4 and IL-5 inhibition with equivalent clinical activity 6

Clinical Efficacy Comparison

Seasonal Allergic Rhinitis

Real-world evidence from the MASK study showed similar symptom control between mometasone furoate and fluticasone propionate 7. In network meta-analysis, mometasone furoate ranked highest for efficacy in seasonal AR, though the difference from fluticasone propionate was minimal 8.

Perennial Rhinitis

A head-to-head trial demonstrated no statistical difference between mometasone furoate 200 mcg and fluticasone propionate 200 mcg once daily 9:

• Symptom reduction from baseline: 37% vs 39% respectively
• Both were significantly superior to placebo (22% reduction)
• Both were well tolerated with no evidence of tachyphylaxis

A more recent study in chronic rhinosinusitis found no significant difference between mometasone furoate and fluticasone furoate nasal sprays, though both improved symptoms significantly 10.

Practical Clinical Considerations

When to Choose Each Agent

Choose either agent based on:

• Cost and insurance coverage (often the deciding factor)
• Patient age: Mometasone if treating children 2-3 years old
• Patient preference: Both are once-daily dosing with similar tolerability

Both agents:

• Require several days to reach maximum effect (not immediate relief like antihistamines) 1
• Should be used continuously during allergen exposure for optimal control
• Do not increase blood pressure when used as directed 1
• Have low rates of adverse events (epistaxis, dysgeusia)

Common Pitfalls to Avoid

1. Expecting immediate relief: Counsel patients that intranasal corticosteroids take 2-7 days for full effect; consider adding intranasal antihistamine for immediate symptom control in moderate-to-severe cases 11

2. Discontinuing when symptoms improve: Patients should continue daily use throughout allergen exposure period 1

3. Improper technique: Ensure patients prime the pump and aim spray away from nasal septum to prevent epistaxis

4. Exceeding duration limits in children: Monitor growth velocity in children requiring prolonged use (>2 months/year for ages 4-11) 1

5. Using supratherapeutic doses: At standard doses (200 mcg/day), systemic effects are negligible for both agents; avoid dose escalation beyond recommended limits

Bottom Line

Select either mometasone furoate or fluticasone propionate based on formulary availability, cost, and patient age—clinical outcomes are equivalent at standard doses. Both provide effective once-daily control of allergic rhinitis symptoms with minimal systemic effects when used as directed 3, 9, 8.